# A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma

> **NCT01649856** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 572 (actual)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse

## Interventions

- **DRUG:** CHOP
- **DRUG:** rituximab [MabThera/Rituxan]
- **DRUG:** rituximab [MabThera/Rituxan]

## Key facts

- **NCT ID:** NCT01649856
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-24
- **Primary completion:** 2014-10-21
- **Final completion:** 2016-09-16
- **Target enrollment:** 572 (ACTUAL)
- **Last updated:** 2017-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01649856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01649856, "A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01649856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*